Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Bunse, Mario Dr. (1) Clauß, Julian (1) Höpken, Uta Elisabeth PD Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (1) Kammertöns, Thomas Dr. (3) Leisegang, Matthias Prof. Dr. rer. nat. (1) Na, Il-Kang Dr. (1) Rehm, Armin Dr. (1) Schmitt, Clemens Prof. Dr. (1) Uckert, Wolfgang Prof. Dr. (2) Willimsky, Gerald Dr. (3) (-) Blankenstein, Thomas Prof. Dr. (10) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) 2011 (5) (-) 2012 (6) 2013 (11) 2014 (3) 2015 (3) 2016 (4) 2017 (6) (-) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (4) 2024 (2) Animal Phenotyping (1) Cancer Genetics and Cellular Stress Responses (1) Cardiac MRI (2) Epigenetic Regulation and Chromatin Architecture (1) Genetics and Genomics of Cardiovascular Diseases (2) Immune Regulation and Cancer (1) Molecular Biology of Peptide Hormones (1) Molecular Cardiovascular Research (1) Molecular Genetics of Chronic Inflammation and Allergic Disease (1) (-) Molecular Immunology and Gene Therapy (10) Molecular Physiology of Somatic Sensation (1) Systems Biology of Gene Regulatory Elements (2) 10 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Molecular Immunology and Gene Therapy20122018 Sort: Result score Newest to oldest Oldest to newest August 30, 2018 / Blood Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice D. Hoser C. Schön C. Loddenkemper P. Lohneis A.A. Kühl T. Sommermann T. Blankenstein G. Willimsky April, 2012 / Nat Rev Cancer The determinants of tumour immunogenicity T. Blankenstein P.G. Coulie E. Gilboa E.M. Jaffee March 30, 2012 / PLoS ONE Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice A. Gerbitz M. Sukumar F. Helm A. Wilke C. Friese C. Fahrenwaldt F.M. Lehmann C. Loddenkemper T. Kammertoens J. Mautner C.A. Schmitt T. Blankenstein G.W. Bornkamm October, 2012 / Transgenic Res Depot formation of doxycycline impairs Tet-regulated gene expression in vivo K. Anders C. Buschow J. Charo T. Blankenstein October 01, 2012 / Int J Cancer B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin) T. Kammertoens Z. Qin D. Briesemeister A. Bendelac T. Blankenstein December, 2012 / Cytokine Differences in serum cytokine levels between wild type mice and mice with a targeted mutation suggests necessity of using control littermates D. Briesemeister C. Friese C.C. Isern E. Dietz T. Blankenstein C. Thoene-Reineke T. Kammertoens November, 2012 / Arzneimittelforschung Spontaneous and therapy-induced T cell responses to cancer T. Blankenstein January, 2018 / Cancer Immunol Res A transgenic dual-luciferase reporter mouse for longitudinal and functional monitoring of T cells in vivo M. Szyska S. Herda S. Althoff A. Heimann J. Russ D. D'Abundo T.M. Dang I. Durieux B. Dörken T. Blankenstein I.K. Na June, 2018 / Cancer Res ERAP1-dependent antigen cross-presentation determines efficacy of adoptive T cell therapy in mice K. Schmidt C. Keller A.A. Kühl A. Textor U. Seifert T. Blankenstein G. Willimsky P.M. Kloetzel August, 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein
August 30, 2018 / Blood Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice D. Hoser C. Schön C. Loddenkemper P. Lohneis A.A. Kühl T. Sommermann T. Blankenstein G. Willimsky
April, 2012 / Nat Rev Cancer The determinants of tumour immunogenicity T. Blankenstein P.G. Coulie E. Gilboa E.M. Jaffee
March 30, 2012 / PLoS ONE Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice A. Gerbitz M. Sukumar F. Helm A. Wilke C. Friese C. Fahrenwaldt F.M. Lehmann C. Loddenkemper T. Kammertoens J. Mautner C.A. Schmitt T. Blankenstein G.W. Bornkamm
October, 2012 / Transgenic Res Depot formation of doxycycline impairs Tet-regulated gene expression in vivo K. Anders C. Buschow J. Charo T. Blankenstein
October 01, 2012 / Int J Cancer B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin) T. Kammertoens Z. Qin D. Briesemeister A. Bendelac T. Blankenstein
December, 2012 / Cytokine Differences in serum cytokine levels between wild type mice and mice with a targeted mutation suggests necessity of using control littermates D. Briesemeister C. Friese C.C. Isern E. Dietz T. Blankenstein C. Thoene-Reineke T. Kammertoens
November, 2012 / Arzneimittelforschung Spontaneous and therapy-induced T cell responses to cancer T. Blankenstein
January, 2018 / Cancer Immunol Res A transgenic dual-luciferase reporter mouse for longitudinal and functional monitoring of T cells in vivo M. Szyska S. Herda S. Althoff A. Heimann J. Russ D. D'Abundo T.M. Dang I. Durieux B. Dörken T. Blankenstein I.K. Na
June, 2018 / Cancer Res ERAP1-dependent antigen cross-presentation determines efficacy of adoptive T cell therapy in mice K. Schmidt C. Keller A.A. Kühl A. Textor U. Seifert T. Blankenstein G. Willimsky P.M. Kloetzel
August, 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein